EUVIMEDObjevte EUVIMED
EditorialOpen access

Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?

Axel De Greef iD, Marie Baeck iD

Journal of the European Academy of Dermatology and Venereology · 2026-08 · 40 (8) · 1294-1295

DOI: 10.1111/jdv.70534 ↗

At a glance

Editorial in Journal of the European Academy of Dermatology and Venereology, published online on 2026-07-31. Written by Axel De Greef and 1 co-authors. Institution: Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium. 5 references. The full text is freely available in PubMed Central.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Není k dispozici žádný abstrakt.

Authors and institutions

  • Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology Pole (LUNS), Université catholique de Louvain (UCLouvain), Brussels, Belgium.

ORCID profiles: Axel De Greef, Marie Baeck

Cite

APA

De Greef, A., & Baeck, M. (2026). Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?. Journal of the European Academy of Dermatology and Venereology, 40(8), 1294-1295. https://doi.org/10.1111/jdv.70534

Vancouver

De Greef A, Baeck M. Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?. Journal of the European Academy of Dermatology and Venereology. 2026;40(8):1294-1295. doi:10.1111/jdv.70534

BibTeX
@article{DeGreef2026,
  author = {De Greef, Axel and Baeck, Marie},
  title = {Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {1294--1295},
  doi = {10.1111/jdv.70534}
}
Start for free →